CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,180 enrolled
Drug / intervention
Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04647396
NCT04647396N/ACompleted

Biomarker- Guided Intervention to Prevent Acute Kidney Injury After Major Surgery. A Prospective Randomized Controlled Multicenter Trial (BigpAK-2)

University Hospital Muenster·interventional·Posted Nov 30, 2020·Updated Nov 12, 2024

In Brief

A clinical study evaluating Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle) for Acute Kidney Injury. Completed, enrolled 1,180 participants across 37 sites in 7 countries.

Detailed Summary

There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. The investigators hypothesize that the implementation of a bundle of supportive measures adapted to patients undergoing major surgery reduces the occurrence of AKI. This randomized prospective multicenter trial is needed to investigator whether the implementation of the bundle of measures is effective to prevent AKI in high risk patients undergoing major surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom
CollaboratorsBioMérieux

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 30, 2020
Enrollment StartNov 17, 2020
Primary CompletionJun 24, 2024
Study CompletionSep 9, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.6 years ago

Interventions

Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle)other

Implementation of the KDIGO bundle for at least 12 hours 1. discontinuation of all nephrotoxic drugs when possible 2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring) 3. close monitoring of serum creatinine, fluid balance and urinary output 4. avoidance of hyperglycemia 5. considerations of alternatives to radiocontrast agents 6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period 7. avoidance of HES, gelatin, and chlorid-rich solutions